In preparation for the CADTH submission for a manufacturer’s drug Anakinra (Kineret) for the treatment of Still’s disease in children and adults, the Canadian Arthritis Patient Alliance in collaboration with the Arthritis Society and Cassie and Friends developed a survey to hear directly from people living with Still’s disease and SJIA about their experiences with these conditions and any experiences taking Anakinra (Kineret). The survey was shared via e-mails, social media and the CAPA newsletter through our respective Canadian networks and communities. The survey was open from December 12, 2020 until January 3, 2021. We are now pleased to share the submission with our readers here.